These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 3709668

  • 1. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists.
    Meller E, Helmer-Matyjek E, Bohmaker K, Adler CH, Friedhoff AJ, Goldstein M.
    Eur J Pharmacol; 1986 Apr 16; 123(2):311-4. PubMed ID: 3709668
    [Abstract] [Full Text] [Related]

  • 2. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
    Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M.
    Mol Pharmacol; 1987 Jun 16; 31(6):592-8. PubMed ID: 2885734
    [Abstract] [Full Text] [Related]

  • 3. The effects of pertussis toxin on dopamine D2 and serotonin 5-HT1A autoreceptor-mediated inhibition of neurotransmitter synthesis: relationship to receptor reserve.
    Bohmaker K, Bordi F, Meller E.
    Neuropharmacology; 1992 May 16; 31(5):451-9. PubMed ID: 1356248
    [Abstract] [Full Text] [Related]

  • 4. Receptor reserve at striatal dopamine receptors modulating the release of [3H]dopamine.
    Yokoo H, Goldstein M, Meller E.
    Eur J Pharmacol; 1988 Oct 18; 155(3):323-7. PubMed ID: 3234490
    [Abstract] [Full Text] [Related]

  • 5. Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity.
    Meller E, Enz A, Goldstein M.
    Eur J Pharmacol; 1988 Oct 11; 155(1-2):151-4. PubMed ID: 2907486
    [Abstract] [Full Text] [Related]

  • 6. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y, Fage D, Zivkovic B, Scatton B.
    J Pharmacol Exp Ther; 1985 Feb 11; 232(2):519-25. PubMed ID: 2857197
    [Abstract] [Full Text] [Related]

  • 7. Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors.
    Meller E, Bohmaker K, Goldstein M, Basham DA.
    Eur J Pharmacol; 1993 Nov 02; 249(1):R5-6. PubMed ID: 7904244
    [Abstract] [Full Text] [Related]

  • 8. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Nov 02; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 9. Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum.
    Enz A, Goldstein M, Meller E.
    Mol Pharmacol; 1990 Apr 02; 37(4):560-5. PubMed ID: 1970116
    [Abstract] [Full Text] [Related]

  • 10. (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis.
    Clark D, Hjorth S, Carlsson A.
    Eur J Pharmacol; 1984 Oct 30; 106(1):185-9. PubMed ID: 6099268
    [Abstract] [Full Text] [Related]

  • 11. Delayed inhibition of dopamine synthesis by gamma-butyrolactone and baclofen: dopamine autoreceptor supersensitivity?
    Argiolas A, Fadda F, Melis MR, Marcou M, Porceddu ML, Gessa GL.
    Eur J Pharmacol; 1982 Nov 05; 85(1):23-7. PubMed ID: 6818043
    [Abstract] [Full Text] [Related]

  • 12. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
    Yasuda Y, Kikuchi T, Suzuki S, Tsutsui M, Yamada K, Hiyama T.
    Life Sci; 1988 Nov 05; 42(20):1941-54. PubMed ID: 3130534
    [Abstract] [Full Text] [Related]

  • 13. Effect of aging on recovery of striatal dopamine receptors following N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) blockade.
    Henry JM, Roth GS.
    Life Sci; 1984 Aug 20; 35(8):899-904. PubMed ID: 6482680
    [Abstract] [Full Text] [Related]

  • 14. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors.
    Jeziorski M, White FJ.
    Synapse; 1989 Aug 20; 4(4):267-80. PubMed ID: 2603146
    [Abstract] [Full Text] [Related]

  • 15. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O, Biggio G.
    Brain Res; 1990 Nov 12; 533(1):53-9. PubMed ID: 1982234
    [Abstract] [Full Text] [Related]

  • 16. Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis.
    Cox RF, Waszczak BL.
    Brain Res; 1990 Nov 26; 534(1-2):273-82. PubMed ID: 1981482
    [Abstract] [Full Text] [Related]

  • 17. Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: single unit recording studies after partial inactivation of receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
    Cox RF, Waszczak BL.
    Mol Pharmacol; 1989 Jan 26; 35(1):125-31. PubMed ID: 2563304
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE, Haubrich DR, Williams M.
    Eur J Pharmacol; 1981 Nov 19; 76(1):15-23. PubMed ID: 7318920
    [Abstract] [Full Text] [Related]

  • 19. D-1 type of dopamine autoreceptors are not involved in the regulation of dopamine synthesis in the striatum.
    Watanabe H, Suda H, Sekihara S, Nomura Y.
    Jpn J Pharmacol; 1987 Mar 19; 43(3):327-30. PubMed ID: 3495683
    [Abstract] [Full Text] [Related]

  • 20. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.
    Hess EJ, Battaglia G, Norman AB, Creese I.
    Mol Pharmacol; 1987 Jan 19; 31(1):50-7. PubMed ID: 3100940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.